Evidence map›Paper›PMID 37646253›Full record

Observational studyTherapeutic advances in respiratory disease

Arterial lactate as a risk factor for death in respiratory failure related to coronavirus disease 2019: an observational study.

Giorgio Maraziti, Laura Marchini, Greta Barbieri, Marco Falcone, Francesco Corradi, Mara Graziani, Lorenzo Ghiadoni, Cecilia Becattini

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Giorgio MarazitiInternal Cardiovascular and Emergency Medicine-Stroke Unit, S. Maria della Misericordia Hospital, University of Perugia, Perugia 06156, Italy.ORCID 0000-0002-9252-1297
Laura MarchiniInternal Cardiovascular and Emergency Medicine-Stroke Unit, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Greta BarbieriDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Marco FalconeInfectious Disease Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Francesco CorradiDepartment of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
Mara GrazianiInternal Cardiovascular and Emergency Medicine-Stroke Unit, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
Lorenzo GhiadoniEmergency Medicine Unit, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Cecilia BecattiniInternal Cardiovascular and Emergency Medicine-Stroke Unit, S. Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
University of Perugia · ITUniversity of Pisa · ITAzienda Ospedaliera Universitaria Pisana · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArterial lactate is a recognized biomarker associated with death in critically ill patients. The prognostic role of arterial lactate in acute respiratory failure due to the novel coronavirus disease 2019 (COVID-19) is unclear.

objectivesWe aimed to investigate the prognostic role of arterial lactate levels at admission in patients with COVID-19-related acute respiratory failure. DESIGN AND

methodsCohorts of consecutive patients admitted to nonintensive care units (ICU) at study centers for COVID-19-related respiratory failure were merged into a collaborative database. The prognostic role of lactate levels at admission was assessed for continuous values and values ⩾2.0 mmol/l, and lactate clearance at 24 h through delta-lactate (ΔLac). The study outcome was 30-day in-hospital death. Cox proportional regression model was used to assess independent predictors of the study outcome.

resultsAt admission, 14.6% of patients had lactate levels ⩾2 mmol/l. In-hospital death at 30 days occurred in 57 out of 206 patients; 22.3% and 56.7% with normal or ⩾ 2 mmol/l lactate at admission, respectively. The median lactate level was 1.0 [interquartile range (IQR) 0.8-1.3] mmol/l and 1.3 (IQR 1.0-2.1) mmol/l in survivors and nonsurvivors, respectively (

conclusionsIn our study, increased arterial lactate at admission was independently associated with in-hospital death at 30 days in non-ICU patients with acute respiratory failure related to COVID-19.

Indexed as

COVID-19Respiratory Distress SyndromeRespiratory InsufficiencyHospital MortalityHumansIntensive Care UnitsLactic AcidRetrospective StudiesRisk FactorsLactic Acidadult respiratory distress syndromeCOVID-19lactaterespiratory insufficiency

Identifiers

PMID37646253
PMCPMC10469239
OpenAlexW4386271828

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.